Aspirin for primary prevention of CV events: yes or no?

Media formats available:

Results with novel FXI inhibitor in AF set the stage for phase 3 trials
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
AHA 2023
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
- Christian Ruff, MD
International survey of secondary prevention of CHD
International survey of secondary prevention of CHD
ESC Congress 2023
International survey of secondary prevention of CHD
- John W. McEvoy, MD, PhD
- Joris Holtrop, MD
What is the best antithrombotic treatment post-PCI?
What is the best antithrombotic treatment post-PCI?
ESC Congress 2023
What is the best antithrombotic treatment post-PCI?
- Marco Valgimigli, MD, PhD
No signal for efficacy of DOAC in patients with atrial high-rate episodes
No signal for efficacy of DOAC in patients with atrial high-rate episodes
ESC Congress 2023
No signal for efficacy of DOAC in patients with atrial high-rate episodes
- Paulus Kirchhof, MD

PACE-CME